NCT06241950View on ClinicalTrials.gov

A Gene Transfer Therapy Study to Evaluate the Safety and Efficacy of Delandistrogene Moxeparvovec (SRP-9001) Following Imlifidase Infusion in Participants With Duchenne Muscular Dystrophy (DMD) Determined to Have Pre-existing Antibodies to Recombinant Adeno-Associated Virus Serotype (rAAVrh74)

PHASE1Enrolling by invitationINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

January 29, 2024

Primary Completion Date

January 31, 2026

Study Completion Date

October 31, 2027

Conditions
Duchenne Muscular Dystrophy
Interventions
GENETIC

delandistrogene moxeparvovec

Single IV infusion of delandistrogene moxeparvovec

BIOLOGICAL

imlifidase

IV infusion of Imlifidase

Trial Locations (1)

08950

Hospital Sant Joan de Déu, Barcelona

Sponsors

Collaborators (1)

Hansa Biopharma AB
All Listed Sponsors
collaborator

Hansa Biopharma AB

INDUSTRY

lead

Sarepta Therapeutics, Inc.

INDUSTRY

NCT06241950 - A Gene Transfer Therapy Study to Evaluate the Safety and Efficacy of Delandistrogene Moxeparvovec (SRP-9001) Following Imlifidase Infusion in Participants With Duchenne Muscular Dystrophy (DMD) Determined to Have Pre-existing Antibodies to Recombinant Adeno-Associated Virus Serotype (rAAVrh74) | Biotech Hunter | Biotech Hunter